RATIONALE: In atherosclerotic plaques, iron preferentially accumulates in macrophages where it can exert pro-oxidant activities. OBJECTIVE: The objective of this study was, first, to better characterize the iron distribution and metabolism in macrophage subpopulations in human atherosclerotic plaques and, second, to determine whether iron homeostasis is under the control of nuclear receptors, such as the liver X receptors (LXRs). METHODS AND RESULTS: Here we report that iron depots accumulate in human atherosclerotic plaque areas enriched in CD68 and mannose receptor (MR)-positive (CD68(+)MR(+)) alternative M2 macrophages. In vitro IL-4 polarization of human monocytes into M2 macrophages also resulted in a gene expression profile and phenotype favoring iron accumulation. However, M2 macrophages on iron exposure acquire a phenotype favoring iron release, through a strong increase in ferroportin expression, illustrated by a more avid oxidation of extracellular low-density lipoprotein by iron-loaded M2 macrophages. In line, in human atherosclerotic plaques, CD68(+)MR(+) macrophages accumulate oxidized lipids, which activate LXRα and LXRβ, resulting in the induction of ABCA1, ABCG1, and apolipoprotein E expression. Moreover, in iron-loaded M2 macrophages, LXR activation induces nuclear factor erythroid 2-like 2 expression, thereby increasing ferroportin expression, which, together with a decrease of hepcidin mRNA levels, promotes iron export. CONCLUSIONS: These data identify a role for M2 macrophages in iron handling, a process regulated by LXR activation.
RATIONALE: In atherosclerotic plaques, iron preferentially accumulates in macrophages where it can exert pro-oxidant activities. OBJECTIVE: The objective of this study was, first, to better characterize the iron distribution and metabolism in macrophage subpopulations in humanatherosclerotic plaques and, second, to determine whether iron homeostasis is under the control of nuclear receptors, such as the liver X receptors (LXRs). METHODS AND RESULTS: Here we report that iron depots accumulate in humanatherosclerotic plaque areas enriched in CD68 and mannose receptor (MR)-positive (CD68(+)MR(+)) alternative M2 macrophages. In vitro IL-4 polarization of human monocytes into M2 macrophages also resulted in a gene expression profile and phenotype favoring iron accumulation. However, M2 macrophages on iron exposure acquire a phenotype favoring iron release, through a strong increase in ferroportin expression, illustrated by a more avid oxidation of extracellular low-density lipoprotein by iron-loaded M2 macrophages. In line, in humanatherosclerotic plaques, CD68(+)MR(+) macrophages accumulate oxidized lipids, which activate LXRα and LXRβ, resulting in the induction of ABCA1, ABCG1, and apolipoprotein E expression. Moreover, in iron-loaded M2 macrophages, LXR activation induces nuclear factor erythroid 2-like 2 expression, thereby increasing ferroportin expression, which, together with a decrease of hepcidin mRNA levels, promotes iron export. CONCLUSIONS: These data identify a role for M2 macrophages in iron handling, a process regulated by LXR activation.
Entities:
Keywords:
atherosclerosis; iron; macrophages; receptors, cytoplasmic and nuclear
Authors: Jacob R Hascalovici; Wei Song; Jacob Vaya; Soliman Khatib; Bianca Fuhrman; Michael Aviram; Hyman M Schipper Journal: J Neurochem Date: 2008-11-15 Impact factor: 5.372
Authors: Joseph J Boyle; Heather A Harrington; Emma Piper; Kay Elderfield; Jaroslav Stark; Robert C Landis; Dorian O Haskard Journal: Am J Pathol Date: 2009-03 Impact factor: 4.307
Authors: Frank D Kolodgie; Herman K Gold; Allen P Burke; David R Fowler; Howard S Kruth; Deena K Weber; Andrew Farb; L J Guerrero; Motoya Hayase; Robert Kutys; Jagat Narula; Aloke V Finn; Renu Virmani Journal: N Engl J Med Date: 2003-12-11 Impact factor: 91.245
Authors: Nikita G Nikiforov; Natalia V Elizova; Michael Bukrinsky; Larisa Dubrovsky; Vsevolod J Makeev; Yoshiyuki Wakabayashi; Poching Liu; Kathy K Foxx; Howard S Kruth; Xueting Jin; Emile R Zakiev; Alexander N Orekhov Journal: Curr Pharm Des Date: 2017 Impact factor: 3.116
Authors: Rajeev Malhotra; Florian Wunderer; Hanna J Barnes; Aranya Bagchi; Mary D Buswell; Caitlin D O'Rourke; Charles L Slocum; Clara D Ledsky; Kathryn M Peneyra; Haakon Sigurslid; Benjamin Corman; Kimberly B Johansson; David K Rhee; Kenneth D Bloch; Donald B Bloch Journal: Arterioscler Thromb Vasc Biol Date: 2019-02 Impact factor: 8.311
Authors: Xiaoyan Yang; Seong-Hoon Park; Hsiang-Chun Chang; Jason S Shapiro; Athanassios Vassilopoulos; Konrad T Sawicki; Chunlei Chen; Meng Shang; Paul W Burridge; Conrad L Epting; Lisa D Wilsbacher; Supak Jenkitkasemwong; Mitchell Knutson; David Gius; Hossein Ardehali Journal: J Clin Invest Date: 2017-03-13 Impact factor: 14.808
Authors: Florian Wunderer; Lisa Traeger; Haakon H Sigurslid; Patrick Meybohm; Donald B Bloch; Rajeev Malhotra Journal: Pharmacol Res Date: 2020-01-25 Impact factor: 7.658